Results 161 to 170 of about 18,962 (231)

Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5649-5657, July 2026.
ABSTRACT Aims To examine whether on‐treatment changes in kidney function and cardiometabolic markers are associated with the magnitude of heart failure (HF) risk reduction across large‐scale trials of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs).
Masashi Hasebe, Hisashi Kamido, Chen‐Yang Su, Yamato Keidai, Daisuke Yabe, Satoshi Yoshiji   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Gastroenterology Res
Weng J, Huang A, Berake TB, Chen SL, Yan BM, Karagozian R.   +5 more
europepmc   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5527-5541, July 2026.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

A brain reward circuit inhibited by next-generation weight-loss drugs in mice. [PDF]

Nature
Godschall EN, Gungul TB, Sajonia IR, Buyukaksakal AK, Li O, Ogilvie S, Keeler AB, Tian G, Shi Y, Koita O, Guo CX, Deutsch TCJ, Steacy EJ, Crook M, Zhang Y, Conley NJ, Memi G, Webster AN, Yipkin Calhan O, Liu W, Akkoub A, Malik K, West KI, Michel-Le S, Karthikeyan A, van Gerven G, Dell'Aglio OA, Beier KT, Zweifel LS, Patel MK, Campbell JN, Deppmann CD, Güler AD.   +32 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

A rapid review of the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes. [PDF]

Drug Alcohol Depend Rep
Leach M, Marziali ME, Parashar S, Bondy G, Guillemi S, Harris M, Hull M, Stone S, Kooij KW, Hogg RS, Montaner JSG.   +10 more
europepmc   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5704-5714, July 2026.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis. [PDF]

J Diabetes Investig
Wang X, Qin J, Liu Y, Wang X.
europepmc   +1 more source

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5787-5802, July 2026.
ABSTRACT Aims Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to ...
Francesco Zaccardi, Vanita R. Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J. Davies   +8 more
wiley   +1 more source

MC4R-related monogenic obesity in children: insights from 2 cases. [PDF]

Ann Pediatr Endocrinol Metab
Shanmugam D, Sridhar S, Kuppusamy N, Manjini K, Sreenivasan P, Kumar MA.   +5 more
europepmc   +1 more source